Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non–small cell lung cancer

Concurrent chemoradiotherapy (CCRT) has become the standard of care for patients with unresectable stage III non–small cell lung cancer (NSCLC). The comparative merits of two widely used regimens: carboplatin/paclitaxel (PC) and cisplatin/etoposide (PE), each with concurrent radiotherapy, remain lar...

Descripción completa

Detalles Bibliográficos
Autores principales: Liew, Mun Sem, Sia, Joseph, Starmans, Maud H W, Tafreshi, Ali, Harris, Sam, Feigen, Malcolm, White, Shane, Zimet, Allan, Lambin, Philippe, Boutros, Paul C, Mitchell, Paul, John, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892396/
https://www.ncbi.nlm.nih.gov/pubmed/24403265
http://dx.doi.org/10.1002/cam4.142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892396/
https://www.ncbi.nlm.nih.gov/pubmed/24403265
http://dx.doi.org/10.1002/cam4.142

Ejemplares similares